Effect of palmitoylethanolamide on visual field damage progression in normal tension glaucoma patients: Results of an open-label six-month follow-up

Ciro Costagliola, Mario R. Romano, Roberto Dell'Omo, Andrea Russo, Rodolfo Mastropasqua, Francesco Semeraro

Research output: Contribution to journalArticle

Abstract

The purpose of this study is to assess the effect of palmitoylethanolamide (PEA) oral administration on intraocular pressure (IOP) and visual field damage progression in normal-tension glaucoma (NTG) patients. Thirty-two consecutive patients affected by NTG were enrolled and randomized in a 1:1 ratio to receive PEA treatment (group A) or no treatment (group B). Group A patients took ultramicronized 300mg PEA tablets two times per day for six months. Best-corrected visual acuity (BCVA), IOP, and visual field test were evaluated at baseline and at the end of the six-month follow-up. No significant differences in clinical parameters between the two groups were observed at baseline. At six months, group A patients showed significant IOP reduction (from 14.4±3.2mm Hg to 11.1±4.3mm Hg, p

Original languageEnglish
Pages (from-to)949-954
Number of pages6
JournalJournal of Medicinal Food
Volume17
Issue number9
DOIs
Publication statusPublished - Sep 1 2014

Keywords

  • glaucoma progression
  • intraocular pressure
  • normal tension glaucoma
  • palmitoylethanolamide
  • visual field

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics
  • Medicine(all)

Fingerprint Dive into the research topics of 'Effect of palmitoylethanolamide on visual field damage progression in normal tension glaucoma patients: Results of an open-label six-month follow-up'. Together they form a unique fingerprint.

  • Cite this